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Abstract  
Background Context: Disc degeneration is the leading cause of low back pain and is often characterized by a 
loss of disc height, resulting from cleavage of chondroitin sulfate proteoglycans (CSPGs) present in the nucleus 
pulposus. Intact CSPGs are critical to water retention and maintenance of the nucleus osmotic pressure. De-
cellularization of healthy nucleus pulposus tissue has the potential to serve as an ideal matrix for tissue engi-
neering of the disc because of the presence of native disc proteins and CSPGs. Injectable in situ gelling matrices 
are the most viable therapeutic option to prevent damage to the anulus fibrosus and future disc degeneration. 
Purpose: The purpose of this research was to create a gentle decellularization method for use on healthy nucleus 
pulposus tissue explants and to develop an injectable formulation of this matrix to enable therapeutic use with-
out substantial tissue disruption. 
Study Design: Porcine nuclei pulposi were isolated, decellularized, and solubilized. Samples were assessed to 
determine the degree of cell removal, matrix maintenance, gelation ability, cytotoxic residuals, and native cell 
viability. 
Methods: Nuclei pulposi were decellularized using serial detergent, buffer, and enzyme treatments. Decellular-
ized nuclei pulposi were solubilized, neutralized, and buffered. The efficacy of decellularization was assessed 
by quantifying DNA removal and matrix preservation. An elution study was performed to confirm removal of 
cytotoxic residuals. Gelation kinetics and injectability were quantified. Long-term in vitro experiments were 
performed with nucleus pulposus cells to ensure cell viability and native matrix production within the inject-
able decellularized nucleus pulposus matrices. 
Results: This work resulted in the creation of a robust acellular matrix (>96% DNA removal) with highly pre-
served sulfated glycosaminoglycans (>47%), and collagen content and microstructure similar to native nucleus 
pulposus, indicating preservation of disc components. Furthermore, it was possible to create an injectable for-
mulation that gelled in situ within 45 minutes and formed fibrillar collagen with similar diameters to native 
nucleus pulposus. The processing did not result in any remaining cytotoxic residuals. Solubilized decellular-
ized nucleus pulposus samples seeded with nucleus pulposus cells maintained robust viability (>89%) up to 21 
days of culture in vitro, with morphology similar to native nucleus pulposus cells, and exhibited significantly 
enhanced sulfated glycosaminoglycans production over 21 days.  
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Introduction 
Low back pain will affect 70% to 80% of the population 
at some point in their lifetime, and disc degeneration is 
the leading cause of low back pain [1]. Disc degenera-
tion is characterized by a loss of intervertebral disc (IVD) 
height, reduced water content, end plate thickening, and 
annular fissures [2–7]. Breakdown of the nucleus pulpo-
sus, a gelatinous matrix rich in collagen type II and chon-
droitin sulfate proteoglycans (CSPGs) [8,9], has been 
implicated in disc degeneration [10]. The CSPGs have 
sulfated glycosaminoglycan (sGAG) side chains that at-
tract water, enabling the nucleus to withstand substantial 
compressive loads and prevent nerve ingrowth [8,9,11]. 
Cleavage of the CSPGs and consequent loss of sGAG side 
chains have been implicated in disease progression by 
resulting in the loss of the ability of the nucleus to hold 
water and therefore bear compressive loads [10]. The 
loss of CSPGs may additionally enable innervation of the 
disc and subsequent pain [11,12]. Discogenic pain is one 
source of low back pain that is thought to arise from in-
creased nociceptive fiber innervation in the IVD [13,14]. 
A variety of approaches are currently being investi-
gated to repair the nucleus pulposus and prevent low 
back pain from occurring. Tissue engineering approaches 
often combine growth factors and cells to attempt to re-
pair the nucleus pulposus; however, in the harsh cata-
bolic environment of the degenerating disc, growth fac-
tors and cells cannot survive [15–20]. The addition of a 
biomaterial carrier has the potential to increase cell via-
bility and enable long-term growth factor delivery. Var-
ious synthetic and natural materials are currently be-
ing investigated for nucleus pulposus tissue engineering 
[21–26]. However, synthetic materials, such as chemi-
cally modified hyaluronan, can have toxic byproducts or 
result in a foreign body response [27–29]. 
An ideal solution for tissue engineering of the nucleus 
pulposus would (1) mimic the native disc composition 
and consist of a proteoglycan rich matrix to restore the 
hydrostatic compressive resistance of the disc, (2) serve 
as a cell carrier, (3) prevent innervation into the nucleus, 
and (4) be deliverable via injection and in situ gelation. 
Decellularized nucleus pulposus tissue has the potential 
to be this ideal scaffold because it is composed of native 
disc proteins and proteoglycans with similar structure 
to native disc. In addition, a decellularized scaffold has 
the potential to be developed into an injectable formula-
tion that gels in situ. 
Tissue-derived biomaterials can offer unique advan-
tages over synthetic materials such as limited foreign 
body response, native cell response, and integration into 
surrounding tissue using endogenous enzymes [30–33]. 
However, to minimize immune rejection of the tissue and 
to prevent the need for systemic immunosuppression, it 
is essential to remove cells and antigens. Decellulariza-
tion of tissue is a practice that has been used for decades 
to create naturally derived scaffolds. Removal of cells and 
antigens is essential to preventing an immune response; 
however, decellularization must also maintain the com-
position and structure of the native tissue [33–36]. De-
cellularization techniques have been optimized for the 
heart [37], lung [38], nerve [39], skin [40], brain [41], 
and spinal cord [42], among other tissues, and can in-
volve physical, chemical, and biological methods to lyse 
cells, and subsequently remove cellular debris. Our labo-
ratory has previously developed gentle decellularization 
techniques for nerve tissue to preserve essential proteins, 
proteoglycans, and microstructure [39,43], which would 
be ideal for the delicate nucleus pulposus. To date, some 
research has been performed to create decellularization 
protocols for the nucleus pulposus [44–47], anulus fi-
brosus [48,49], and the intact IVD [50]. These matrices 
have shown promise as viable scaffolds for IVD cells as 
well as drivers of stem cell fate [44–50], although they 
are not injectable or in situ gelling. 
After a tissue has been decellularized, it is possible to 
turn the tissue into an injectable in situ gelling bioma-
terial [37,51], which would enable an easier therapeutic 
delivery with minimally invasive surgery. For IVD, an in-
jectable in situ gelling material would support delivery 
through a fine gauge needle with no disruption of the an-
ulus fibrosus, while also enabling formation of a gel capa-
ble of supplementing load bearing of the nucleus pulpo-
sus. Works by Freytes et al. and Singelyn et al. document 
the early processes to solubilize decellularized urinary 
bladder matrix and heart tissue, enabling in situ gela-
tion by using pepsin in hydrochloric acid [37,51]. Kwon et 
al. used pepsin in acetic acid to solubilize cartilage [52]. 
Others have used modifications of these protocols to solu-
bilize a variety of tissues, including brain [41], liver [53], 
and tendon [54]. However, these protocols have not yet 
been adapted to create injectable in situ gelling hydro-
gels from decellularized nucleus pulposus or IVD tissue. 
The purpose of this research was to create a gentle 
nerve decellularization method for use on the nucleus 
pulposus tissue of the IVD, thereby creating a tissue-spe-
cific acellular matrix with increased maintenance of pro-
teoglycans and sGAGs with the potential to prevent nerve 
ingrowth and drive stem cell fate. In addition, we also 
wanted to create an injectable formulation of this matrix 
to enable therapeutic use without substantial disruption 
of the anulus fibrosus. 
Conclusions: A gentle decellularization of porcine nucleus pulposus followed by solubilization enabled the cre-
ation of an injectable tissue-specific matrix that is well tolerated in vitro by nucleus pulposus cells. These ma-
trices have the potential to be used as a minimally invasive nucleus pulposus therapeutic to restore disc height. 
Keywords: Decellularized matrix, Disc degeneration, Injectable scaffold, Intervertebral disc, Nucleus pulposus, 
Tissue engineering  
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Materials and methods 
Nucleus pulposus harvest and processing 
Whole spines were dissected en bloc from Yorkshire-
Landrace porcine weighing 40 to 50 kg (Fig. 1). Excess 
tissue was removed and spines were disarticulated into 
cervical, thoracic, and lumbar segments. Spine segments 
were stored at −80°C until use. Spine segments were 
then thawed for 24 hours, and the nuclei pulposi were 
isolated from the cervical, thoracic, and lumbar sections 
of the spine using careful dissection, and stored for up to 
1 hour in sterile 1× phosphate buffered saline (PBS) un-
til use (Fig. 2A, B, and C). 
The nuclei pulposi were decellularized using a gen-
tle technique adapted from Hudson et al. previously de-
veloped in our laboratory. All samples were processed in 
15 mL tubes in an orbital shaker at 15 rpm. The samples 
were immersed in water for 7 hours, followed by 100 
mM sodium and 50 mM phosphate buffer for 10 hours, 
SB-10 detergent for 4 hours, 100 mM sodium and 50 mM 
phosphate buffer for 15 minutes, Triton X-200/SB-16 for 
3 hours, 100 mM sodium and 50 mM phosphate buffer 
for 3 × 15 minutes, SB-10 detergent for 1.75 hours, 100 
mM sodium and 50 mM phosphate buffer for 15 min-
utes, Triton X-200/SB-16 for 3 hours, 100 mM sodium 
and 50 mM phosphate buffer for 3 × 15 minutes, and fol-
lowed by DNase/RNase solution (75 U/mL/100μg/mL) for 
34 hours. The decellularized nuclei pulposi (dNPs) were 
then washed in 50 mM sodium and 10 mM phosphate buf-
fer for 3 × 90 min. Macroscopic images of nuclei pulposi 
before and after decellularization are illustrated in Fig. 2. 
DNA removal and sGAG maintenance 
DNA removal and sGAG maintenance were determined 
using quantitative assays. Fresh nucleus pulposus (NP) 
control and dNP samples were fixed in 4% paraformal-
dehyde (PFA) for 30 minutes and washed 3 × 15 minutes 
in 1× PBS. Of each sample, 50 mg wet weight was cut and 
digested in papain (4762, Sigma, St Louis, MO, USA) at 
65°C for 18 hours. After digestion, DNA was analyzed us-
ing a Quant-IT PicoGreen assay (P7589, Thermo Fisher, 
Waltham, MA, USA). The sGAG content was quantified 
using a Blyscan assay (Biocolor, Carrickfergus, Ireland). 
A total of six dNPs were quantified from the cervical, 
Fig. 2. Macroscopic images of nuclei pulposi from the cervical, thoracic, and lumbar spine segments, respectively, before (A, B, C) and af-
ter (D, E, F) decellularization.  
Fig. 1. Macroscopic image of lumbar spine segment after cleaning (Left) and dissection (Right).  
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thoracic, and lumbar segments of three distinct spines 
and compared with matched fresh NP controls. 
Collagen content 
The collagen content of fresh NP control and dNP samples 
was assessed using both soluble and insoluble collagen 
assays. Fifty milligrams of fresh NPs and dNPs were di-
gested in 1 mg/mL pepsin (P7012, Sigma) in 0.5M acetic 
acid at 4°C for a minimum of 18 hours on a shaker plate. 
After digestion, the soluble collagen assay was executed 
followed by the insoluble assay using standard assay kits 
(CLRS1000, CLRS2000, Biocolor). The collagen content 
was normalized to wet weight. A total of six dNPs were 
quantified from three distinct spines and compared with 
six fresh NP controls. 
Cell removal and maintenance of CSPGs 
Cell removal and maintenance of CSPGs after decellu-
larization were qualitatively assessed using fluorescence 
staining and confocal imaging. Decellularized and fresh 
NP samples were fixed in 4% PFA for 30 minutes, washed 
3 × 15 minutes in 1× PBS, and permeablized with 4% 
goat serum and 0.5% Triton X-100 in 1× PBS. Follow-
ing permeabilization, dNP samples were stained over-
night with a primary antibody to CSPGs (C8035, 1:200, 
Sigma) in blocking buffer containing 0.3% Triton X-100 
(93443, Sigma) and 3% goat serum (G9023, Sigma) in 
1× PBS. An Alexa Fluor 568 secondary antibody (A11031, 
1:500, Thermo Fisher) was used to fluorescently label the 
CSPG primary. All samples were then counterstained with 
DAPI (D1306, Thermo Fisher) for 5 minutes and washed 
3 × 5 minutes in 1× PBS. A Zeiss LSM 710 confocal mi-
croscope (Zeiss Microimaging Inc., Jena, Germany) was 
used to take z-stacks through each NP sample. Maximum 
intensity projections were created through z-thickness 
matched samples to enable semi-quantitative analysis. 
Assessment of cytotoxic residuals 
Decellularized NP samples were eluted for 72 hours at 
37°C in 10 mL of medium containing 89% DMEM:F12 
(D8437, Sigma), 10% fetal bovine serum (16000044, 
Life Technologies, Carlsbad, CA, USA), and 1% penicil-
lin-streptomycin (51606, EMD Millipore, Billerica, MA, 
USA). A total of 16 dNPs were eluted from four distinct 
spines (n=3–6 per spine). After 72 hours, eluted medium 
from each sample was removed and 250 _L was added to 
a 48-well plate containing ~7,500 human neonatal der-
mal fibroblasts (PCS-201-010, ATCC, Manassas, VA, USA) 
in triplicate per sample. Control wells containing fresh 
medium were also cultured (n=3). After 48 hours, a met-
abolic assay (DAL1100, Thermo Fisher) was performed to 
assess the metabolic activity of eluted dNP samples me-
dium versus control medium and determine if cytotoxic 
residuals were present. 
Creation of an injectable dNP matrix 
In preparation for solubilization, dNPs were washed three 
times in ddH2O and then lyophilized for 72 hours. After ly-
ophilization, dNPs were cut in small pieces and pooled for 
digestion (Fig. 5B). Chopped dNPs were suspended at 5 mg 
to 20 mg/mL in 1 mg/mL pepsin in either 3% acetic acid 
or 0.01 M hydrochloric acid with or without homogeniza-
tion for 3 × 30 seconds. dNPs were then placed on a stir 
plate at room temperature for 32 to 64 hours to facilitate 
digestion. After 32 to 64 hours, each sample was neutral-
ized using either 0.1M or 1Msodium hydroxide and buff-
ered with 10% of 10× sterile PBS. The ability to thermally 
gel was tested by pipetting 10 to 30 μL of solubilized dNPs 
onto paraffin and incubating for 45 minutes at 37°C. Solu-
bilized dNPs were stored at 4°C for up to 7 days until use. 
Gelation kinetics 
Thermal gelation of collagen occurs through fibrillar for-
mation and crosslinking. As this process occurs, proteins 
aggregate and form cross-links and the absorbance of 
405 nm light increases. This phenomenon can be used 
to determine gelation kinetics by examining the tempo-
ral increase and plateau in absorbance as gelation pro-
gresses to completion. To assess gelation kinetics, 50 μL 
of chilled pre-gel solubilized dNP was placed into a 96-
well plate and absorbance was measured at 405 nm 37°C 
using the Synergy HT Plate Reader (BioTek, Winooski, 
VT, USA). Four batches of injectable dNPs were tested in 
duplicate. Absorbance readings were recorded every 2 
minutes over a total of 60 minutes. Type I collagen gels 
were used as a positive control, and a solution of 3% ace-
tic acid neutralized with 5 M sodium hydroxide and buff-
ered with 10% 10× PBS was used as a negative control. 
Data were normalized to the initial readings using Equa-
tion (1), where A is the absorbance, A0 describes the ini-
tial absorbance, and Amax is the maximum absorbance. 
         Normalized absorbance =    
A – A0 
                                             Amax A0                      
(1) 
Injectability of solubilized dNP matrix 
To test the ability of the solubilized dNPs to be injected 
and still form a gel, the samples were ejected through 
a 30 gauge needle using a maximum force of <200 N, 
which is the maximum applied force for injection by 
hand [55]. After injection, the ability to thermally gel 
was tested by incubating for 45 minutes at 37°C. 
Microstructure 
Decellularized, solubilized and re-gelled, solubilized in-
jected and re-gelled, and fresh NP samples were each 
prepared for scanning electron microscopy. The samples 
were fixed in 4% PFA for 30 minutes, washed 3 × 15 
minutes in 1× PBS, and then subjected to serial ethanol 
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dehydration (30%, 50%, 70%, 85%, 90%, 95%, and 
100%) over the course of 2 hours. After dehydration, 
samples were dried using serial solutions of hexamethyl-
disilazane (25%, 50%, 75%, and 100%) over the course 
of 2 hours. The samples were then left to dry overnight 
in a fume hood in hexamethyldisilazane. High-resolution 
scanning electron microscopy (SEM) was performed us-
ing a Nova NanoSEM (FEI, Hillsboro, OR, USA). Images 
were acquired at magnifications ranging from 5,000× to 
80,000×. ImageJ [56,57] was used to quantify fiber di-
ameter at 20,000× and assess maintenance of structure 
in decellularized, solubilized and re-gelled, solubilized in-
jected and re-gelled, and fresh NP samples. A minimum 
of five images per group were quantified, and a minimum 
of 175 collagen fibers per image were measured. 
NP cell-seeded constructs 
Human nucleus pulposus cells (#4800, ScienCell Re-
search Laboratories, Carlsbad, CA, USA) were cultured 
and passaged in complete medium containing 1% peni-
cillin-streptomycin, 10% fetal bovine serum, and 1% nu-
cleus pulposus cell growth supplement (#4801, ScienCell 
Research Laboratories) at 37°C and in normoxic condi-
tions. Nucleus pulposus cells from passage 1 to 3 were 
gently lifted using trypsin-EDTA (25200056, Thermo 
Fisher) and mixed with solubilized dNP samples. Solubi-
lized dNPs and cell mixtures were pipetted onto parafilm 
in 30 μL droplets (40,000 cells per gel) and incubated 
for 45 minutes at 37°C to allow for thermal gelation. Af-
ter gelation, samples were placed in a 48-well plate and 
immersed in 200 μL of complete medium. Two batches 
of dNPs were cultured for 1, 7, or 21 days under hypoxic 
conditions of 3.5% oxygen and 5% carbon dioxide to 
mimic conditions present in in vivo nucleus pulposus 
(n=6 per time point per batch). 
Viability, sGAG content, and collagen content were de-
termined at each time point. A standard live-dead as-
say using ethidium homodimer and calcein AM (L3224, 
Thermo Fisher) was performed at days 1, 7, and 21 to de-
termine cell viability in gels. After staining, confocal im-
aging was used to image intact gels (LSM 710, Zeiss Mi-
croimaging Inc.). A minimum of three 10× images were 
taken for each gel and quantified using Zeiss ZEN Im-
ageAnalysis software (Zeiss Microimaging Inc.). Z-stack 
images were also acquired to assess cell morphology in 
gels. Sulfated glycosaminoglycan and collagen content 
were analyzed using the methods listed in the DNA Re-
moval and sGAG Maintenance section. 
Statistics 
Paired students t tests were performed to assess differ-
ences between dNPs and fresh NP controls (p<.05) for 
the sGAG quantification, DNA content, collagen content, 
metabolic activity assessment of cytotoxic residuals, and 
SEM fiber diameters. In addition, an analysis of variance 
with Tukey pairwise comparison was used to determine 
differences in viability, sGAG content, and DNA content 
between time points and batches in the nucleus pulpo-
sus cell-seeded construct experiment. 
Results 
DNA, sGAG, and collagen content 
The results indicate that it was possible to create a gentle 
decellularization procedure for porcine nucleus pulposus. 
Over 96% of DNA content was removed in dNPs from cer-
vical, thoracic, and lumbar segments (Fig. 3, Left). In ad-
dition, sGAG preservation was 44.5%, 21.9%, and 50.8% 
for dNPs from cervical, thoracic, and lumbar segments, 
respectively, as shown in Fig. 3, Middle. Because of the 
low sGAG preservation in the thoracic discs, all follow-
ing studies exclusively used cervical and lumbar discs for 
processing and testing. The total collagen content was 
maintained after decellularization, with dNP samples ex-
hibiting a total collagen content of 18.6 μg of collagen per 
milligram wet weight and control NP samples exhibiting 
16.12 μg/mg (Fig. 3, Right). There was no significant dif-
ference between the two groups. 
Cell removal and maintenance of CSPGs 
Confocal imaging revealed faint DAPI staining in the ma-
jority of dNPs, with some containing no areas with any 
DAPI staining. After decellularization, CSPGs were well 
Fig. 3. DNA content was significantly removed in decellularized nuclei pulposi (dNPs) versus fresh nucleus pulposus (NP) controls, with 
greater than 96% DNA being removed in all samples (Left) (p<.05). Sulfated glycosaminoglycans were well maintained (>45%) in the cer-
vical and lumbar nuclei pulposi (Middle) (p<.05). Concentrations of soluble, insoluble, and total collagen were not significantly different 
between the control NP and dNP samples (Right). Data (n=6) represent the mean±standard error.   
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preserved throughout the matrix. Fig. 4 is a represen-
tative image of a control nucleus pulposus (Top) and a 
dNP (Bottom). No differences were observed between 
the spine segments (cervical and lumbar); however, it 
was not possible to quantify staining because of high 
variability in cell density in different areas of the nu-
cleus pulposus. 
Cytotoxicity 
The metabolic activity of human neonatal dermal fibro-
blasts with eluted dNP sample medium was not signif-
icantly lower than the control medium for any of the 
samples tested. Across all samples tested, the average dif-
ference in metabolic activity compared with the control 
medium was 1.11% ±2.1 standard error. This indicates 
that there are no cytotoxic residuals remaining from the 
decellularization process that impact cell function. 
Creation of an injectable dNP matrix 
The optimal parameters for the creation of a robust in-
jectable dNP matrix were achieved by solubilizing minced 
dNPs at 20 mg/mL in 1 mg/mL pepsin in 3% acetic acid, 
homogenizing for 3 × 30 seconds, and stirring at room 
temperature for 32 hours before neutralization and 
buffering (Fig. 5). These gels could be manually manip-
ulated and did not break apart when submerged in 1× 
PBS for up to 7 days. 
Gelation kinetics 
Stabilization of absorbance of all four batches of dNP 
samples occurred by ~40 minutes, indicating near com-
plete gelation. A slope of 0 was observed in all samples 
by 60 minutes, indicating complete gelation. Type I col-
lagen controls (354236, Corning, Corning, NY, USA) ex-
hibited complete gelation in 20 minutes. 
Injectability of solubilized dNP matrix 
The solubilized dNP samples were easily injected through 
a 30 gauge syringe with minimal manual pressure. No 
macroscopic disruption of the matrix was observed, and 
they were able to form a smooth gel surface. Samples 
gelled in ~40 minutes, similar to non-injected solubi-
lized dNP controls. SEM was used to assess any changes 
in microstructure. 
Microstructure preservation 
SEM revealed excellent preservation of microstructure 
after decellularization, and solubilization and re-gelation 
Fig. 4. Cell nuclei were removed (DAPI, left panels, blue) and chondroitin sulfate proteoglycans (CSPGs, right panels, red) were maintained 
after decellularization of nuclei pulposi (Bottom) compared with fresh nuclei pulposi controls (Top).  
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of NP samples (Fig. 6A, B, and C). The collagen fibrils 
were intact and not substantially disrupted. Furthermore, 
no cellular debris was apparent in dNPs. Although fiber 
diameter was significantly increased after decellulariza-
tion compared with controls, and significantly decreased 
after solubilization compared with controls, both diam-
eters were within 10% of the control NP fiber diameter 
(Fig. 6D). The microstructure was also assessed after in-
jection through a fine gauge needle and regelation of the 
dNPs. There was no significant difference in fiber diam-
eter of solubilized dNPs that were gelled without injec-
tion compared with those that were solubilized, injected, 
and then gelled. 
NP cell-seeded constructs 
Nucleus pulposus cells maintained excellent viabil-
ity (>89%) over the entire 21-day culture period, as 
illustrated in Fig. 7, Left, with a significant increase 
observed between day 1 and day 7, and no significant 
differences observed between day 1 or day 7 and day 21. 
In addition, by day 21, NP cells exhibited an elongated 
morphology similar to that observed in native nucleus 
pulposus cells (Fig. 7, Middle). There was an increase 
in sGAG content over the 21-day culture period, which 
was significant by day 21 (Fig. 7, Right). No significant 
difference in DNA content was observed over the 21-day 
culture period. 
Discussion 
This work demonstrates our ability to generate tissue-
specific acellular matrices containing limited cell rem-
nants and intact CSPGs for tissue engineering of the IVD. 
These matrices have no detectable remaining cytotoxic 
residuals and maintain fiber diameters similar to the na-
tive nucleus pulposus. Furthermore, the dNPs are able to 
be modified to create an injectable formulation that can 
support long-term culture of nucleus pulposus cells in vi-
tro, suggesting it will be viable for in vivo studies.  
Fig. 5. Pictorial illustration of the digest and re-gelation process of the decellularized nuclei pulposi, from post-lyophilization (A), to fine 
chop (B), to homogenization (C), and to post-gelation (D).   
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An optimized decellularization process for nucleus 
pulposus needs to balance the removal of cells with the 
maintenance of sGAGs. The sGAGs are essential in main-
taining the osmotic pressure of the nucleus pulposus [8], 
and they have the potential to play a role in driving cell 
phenotype [45–47,50,58] and preventing innervation 
[59–62]. The gentle decellularization protocol used in our 
laboratory for nerve [39,43,63] and lung tissue [38] was 
adapted for use in the nucleus pulposus by shortening the 
duration of wash cycles substantially. The use of ampho-
teric and anionic detergents in short cyclic intervals en-
abled the preservation of nucleus pulposus microstruc-
ture, while also maintaining 45% to 51% of sGAGs and 
removing >96% of DNA, similar to the methods previ-
ously developed by Mercuri et al. [44]. In addition, there 
were no detectable cytotoxic residuals after processing, 
as demonstrated by the elution study. 
Preservation of sGAGs is an indirect indicator of pres-
ervation of CSPGs. In addition, our confocal results indi-
cate preservation of CSPGs after decellularization. CSPGs 
are known to be potent neurite inhibitors [11,12,60,64]. 
By maintaining CSPG presence in the matrix, this has the 
potential to prevent nerve growth into the nucleus pulpo-
sus. Innervation of the nucleus pulposus has been demon-
strated in patients with low back pain [13,14]. The abil-
ity of these solubilized dNP matrices to prevent nerve 
growth in vitro and in vivo is currently being explored. 
One of the major outputs of this work is the creation 
of an in situ gelling decellularized nucleus pulposus. The 
location of the nucleus pulposus inside the anulus fibro-
sus makes it difficult to access without damaging the an-
ulus. Injectable in situ gelling matrices are the most vi-
able therapeutic option to prevent damage to the anulus 
fibrosus and future disc degeneration. Substantial work 
Fig. 6. Scanning electron micrographs at varying magnifications from 5,000× to 10,000× revealed similar fibrillar structure before (A) 
and after (B) decellularization of the nuclei pulposi samples, as well as after solubilization (C). Average fiber diameters at 20,000× of de-
cellularized nuclei pulposi (dNPs) and solubilized dNPs were within 10% of the fresh nuclei pulposi controls (D).  
Fig. 7. Viability of nucleus pulposus cell-seeded gels was high throughout the culture period (>89%) (Left). Nucleus pulposus cells were 
well spread and displayed morphology similar to cells in native tissue by day 21 (Middle) (calcein staining). Sulfated glycosaminoglycan 
content was significantly increased by day 21 (Right) (p<.05). Data (n=6 per time point per batch) represent the mean±standard error.   
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has been performed in other tissue types to create in-
jectable in situ gelling decellularized matrices [37,51,54], 
but no work exists in the IVD. To date, the only injectable 
decellularized nucleus pulposus was developed by Illien-
Jünger et al. [47]. However, this matrix was created by 
grinding the tissue to create small particles that were in-
jected through a 25 gauge needle. This approach does not 
enable in situ gelation and formation of a material able 
to bear loads, and can potentially damage the anulus fi-
brosus. Ideally, a finer gauge needle would be used. Our 
work demonstrates the creation of an in situ gelling de-
cellularized nucleus pulposus that has the ability to act 
as a cell carrier and be injected through a very fine nee-
dle (30 gauge) and still form a stable gel. 
Matrix architecture and composition [65] can drive 
cell fate. Specifically, recent work has demonstrated 
that nucleus pulposus tissue alone has the potential to 
drive stem cells toward an NP phenotype [66,67]. This is 
likely due to the native microstructure as well as compo-
sition. Analysis via SEM revealed fiber diameters of dNP 
samples and injectable dNP samples were within 10% 
of fresh NP control samples. Furthermore, collagen and 
sGAG in the NP extracellular matrix were maintained 
during decellularization. Nucleus pulposus cell-seeded 
gels cultured over 21 days demonstrated high viability, 
NP-like morphology, and significantly increasing sGAG 
content over time, indicating an appropriate matrix en-
vironment. These data support the conclusion that the 
gel fiber morphology and composition of the samples are 
maintained during decellularization and solubilization, 
and have the potential to be ideal matrices for tissue en-
gineering of the nucleus pulposus. Future work will ex-
plore the ability of the injectable dNPs created herein to 
drive both stem cells and induce pluripotent stem cells 
toward a nucleus pulposus cell phenotype. 
Conclusions 
In conclusion, we have created an acellular injectable 
tissue-specific matrix that is well tolerated in vitro by 
nucleus pulposus cells. This new matrix has the poten-
tial to be used for regenerative tissue engineering of the 
nucleus pulposus to restore disc height and prevent un-
wanted painful innervation.    
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